Rebecca Taub
CIK 1423898 · Pres., R&D, and CMO · last filed 2026-03-06
Rebecca Taub is a Pres., R&D, and CMO who has filed 29 SEC Form 4 insider transactions across 2 companies since 2008. The most recent filing shows the insider sold $212.1K of MDGL on Mar 6, 2026. Across all open-market trades the lifetime net is −$47.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $532.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$532.57M
2
29
-$47.03M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Director | 1,107,753 | $480.77 | $532.57M | -$47.04M | 27 | 2026-03-06 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | SVP, Research & Development | 32,500 | — | — | $9.8K | 2 | 2008-12-19 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-06 | MDGL | Sell (S) | −491 | -$212.1K | EDGAR |
| 2026-01-26 | MDGL | Sell (S) | −647 | -$318.6K | EDGAR |
| 2026-01-20 | MDGL | Sell (S) | −2,238 | -$1.10M | EDGAR |
| 2026-01-13 | MDGL | Mixed | — | -$9.33M | EDGAR |
| 2026-01-13 | MDGL | Mixed | — | -$128.3K | EDGAR |
| 2025-12-12 | MDGL | Mixed | −5,455 | -$10.00M | EDGAR |
| 2025-08-13 | MDGL | Mixed | — | -$16.07M | EDGAR |
| 2025-07-22 | MDGL | Mixed | — | -$340.6K | EDGAR |
| 2025-07-18 | MDGL | Mixed | — | -$10.00M | EDGAR |
| 2025-03-07 | MDGL | Grant (A) | +4,382 | $0 | EDGAR |